The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
D- and Unnatural Amino Acid Substituted Antimicrobial Peptides With Improved Proteolytic Resistance and Their Proteolytic Degradation Characteristics
Open accessAbstract
The transition of antimicrobial peptides (AMPs) from the laboratory to market has been severely hindered by their instability toward proteases in biological systems. In the present study, we synthesized derivatives of the cationic AMP Pep05 (KRLFKKLLKYLRKF) by substituting L-amino acid residues with D- and unnatural amino acids, such as D-lysine, D-arginine, L-2,4-diaminobutanoic acid, L-2,3-diaminopropanoic acid, L-homoarginine, 4-aminobutanoic acid (Aib), and L-thienylalanine, and evaluated their antimicrobial activities, toxicities, and stabilities toward trypsin, plasma proteases, and secreted bacterial proteases. In addition to measuring changes in the concentration of the intact peptides, LC-MS was used to identify the degradation products of the modified AMPs in the presence of trypsin and plasma proteases to determine degradation pathways and examine whether the amino acid substitutions afforded improved proteolytic resistance. The results revealed that both D- and unnatural amino acids enhanced the stabilities of the peptides toward proteases. The derivative DP06, in which all of the L-lysine and L-arginine residues were replaced by D-amino acids, displayed remarkable stability and mild toxicity in vitro but only slight activity and severe toxicity in vivo, indicating a significant difference between the in vivo and in vitro results. Unexpectedly, we found that the incorporation of a single Aib residue at the N-terminus of compound UP09 afforded remarkably enhanced plasma stability and improved activity in vivo. Hence, this derivative may represent a candidate AMP for further optimization, providing a new strategy for the design of novel AMPs with improved bioavailability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Access to effective antimicrobials: a worldwide challenge
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00474-2 · Cited by 1,465
Structural characteristics of .alpha.-helical peptide molecules containing Aib residues
Karle, I. L., & Balaram, P. (1990) · Biochemistry · doi:10.1021/bi00481a001 · Cited by 989
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Structure−Activity Relationships of Polymyxin Antibiotics
Velkov, T., Thompson, P. E., Nation, R. L., & Li, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900999h · Cited by 780
Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design
Li, J., Koh, J.-J., Liu, S., Lakshminarayanan, R., Verma, C. S., & Beuerman, R. W. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00073 · Cited by 611
The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms
de Breij, A., Riool, M., Cordfunke, R. A., Malanovic, N., de Boer, L., Koning, R. I., Ravensbergen, E., Franken, M., van der Heijde, T., Boekema, B. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4044 · Cited by 555
Antimicrobial Peptide Structure and Mechanism of Action: A Focus on the Role of Membrane Structure
Lee, T.-H., N. Hall, K., & Aguilar, M.-I. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150703121700 · Cited by 512
Luepke, K. H., Suda, K. J., Boucher, H., Russo, R. L., Bonney, M. W., Hunt, T. D., & Mohr, J. F. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1868 · Cited by 344
Cited by
Design, optimization, and nanotechnology of antimicrobial peptides: From exploration to applications
Tan, P., Fu, H., & Ma, X. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101229 · Cited by 351
Peptide-based drug discovery: Current status and recent advances
Sharma, K., Sharma, K. K., Sharma, A., & Jain, R. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103464 · Cited by 313
Antimicrobial peptides towards clinical application: Delivery and formulation
Wang, C., Hong, T., Cui, P., Wang, J., & Xia, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.028 · Cited by 281
Self-citationAntimicrobial peptides: structure, functions and translational applications
Oliveira Júnior, N. G., Souza, C. M., Buccini, D. F., Cardoso, M. H., & Franco, O. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01200-y · Cited by 276
Advances and prospects of cell-penetrating peptides in tumor immunotherapy
Yang, D., Liu, B., & Sha, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86130-8 · Cited by 31
Metadata
- Authors
- Lu, J., Xu, H., Xia, J., Ma, J., Xu, J., Li, Y., & Feng, J.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2020-11-12
- Volume
- 11
- Pages
- 563030-563030
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W3101923829
- Cited by
- 257
- References
- 36
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: D- and Unnatural Amino Acid Substituted Antimicrobial Peptides With Improved Proteolytic Resistance and Their Proteolytic Degradation Characteristics. https://app.cochat.ai/papers/10.3389/fmicb.2020.563030
- The paper
- Lu, J., Xu, H., Xia, J., Ma, J., Xu, J., Li, Y., & Feng, J. (2020). D- and Unnatural Amino Acid Substituted Antimicrobial Peptides With Improved Proteolytic Resistance and Their Proteolytic Degradation Characteristics. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2020.563030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.